Apixaban News and Research

RSS

Study: Most stroke survivors can safely take two types of common antidepressants

Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2024.

1 Feb 2024

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.

14 Dec 2023

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found.

13 Nov 2023

Modern blood thinners linked to reduced risk of bleeding

Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45 percent compared to the traditional drug Waran in the treatment of blood clots in the legs and lungs.

29 Aug 2023

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models.

10 Jul 2023

A randomized trial of a blood thinner after severe COVID-19 to prevent clotting events

In a recent prospective study published in the Annals of Internal Medicine Journal, researchers in the United States (US) and Spain performed a randomized controlled trial (RCT) across 127 US hospitals between 2021 and 2022.

27 Mar 2023

High-dose anticoagulation can reduce deaths, intubations in hospitalized COVID-19 patients

High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.

6 Mar 2023

Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Giving noncritically ill patients hospitalized for COVID-19 a higher dose of blood-thinning medication than usual did not significantly reduce the combined risk of death from any cause, need for treatment in an intensive-care unit, a confirmed blood clot or a stroke at 30 days, according to the results of the FREEDOM-COVID trial presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

6 Mar 2023

Dual antiplatelet therapy for minor or a warning stroke is underused especially among women

Despite evidence that starting two blood-thinning medications shortly after a minor stroke or a warning stroke (transient ischemic attack - TIA) may prevent a second – possibly more serious – clot-caused stroke within a few months, the treatment regimen is underused especially among women, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2023.

2 Feb 2023

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

4 Jan 2023

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT).

27 Dec 2022

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).

27 Dec 2022

Common psychiatric medications can give some protection against COVID-19

A new meta-analysis shows that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing the strongest effect.

16 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke's Hospital and the University of Cambridge has found.

28 Nov 2022

Oral anticoagulant drug may be safe, effective in preventing blood clots after urologic cancer surgery

The oral anticoagulant drug apixaban may offer a safer, more effective alternative to standard home heparin injections for patients taking extended prophylaxis (EP) to prevent blood-clot-related complications after surgery, reports a study in The Journal of Urology, an Official Journal of the American Urological Association.

12 Sep 2022

Clinical presentation of monkeypox infection in two Israeli males

Researchers described the symptomatology and clinical manifestations of monkeypox infections among two Israeli patients.

12 Jul 2022

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban).

20 May 2022

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Some treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleeding stroke, are not as effective as previously believed, according to the new American Heart Association/American Stroke Association guideline for caring for people with spontaneous ICH, published today in the Association's Stroke journal.

17 May 2022

New type of anti-clotting drug reduces bleeding incidents among patients with atrial fibrillation

A new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of the two.

4 Apr 2022